Avadel Pharmaceuticals (NASDAQ:AVDL - Get Free Report) is expected to announce its Q1 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $50.57 million for the quarter.
Avadel Pharmaceuticals Price Performance
AVDL stock traded up $0.35 during trading on Monday, reaching $9.04. 1,106,375 shares of the company were exchanged, compared to its average volume of 1,222,451. The company has a market capitalization of $873.53 million, a price-to-earnings ratio of -11.44 and a beta of 1.52. The company has a 50-day moving average of $7.99 and a two-hundred day moving average of $9.57. Avadel Pharmaceuticals has a twelve month low of $6.38 and a twelve month high of $19.07.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on AVDL. UBS Group dropped their price target on Avadel Pharmaceuticals from $22.00 to $14.00 and set a "buy" rating for the company in a research note on Monday, January 13th. Deutsche Bank Aktiengesellschaft started coverage on Avadel Pharmaceuticals in a research note on Tuesday, February 11th. They set a "buy" rating and a $12.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $19.00 price objective on shares of Avadel Pharmaceuticals in a research note on Wednesday, April 9th. Piper Sandler cut their target price on shares of Avadel Pharmaceuticals from $24.00 to $13.00 and set an "overweight" rating on the stock in a research report on Friday, January 10th. Finally, HC Wainwright restated a "buy" rating and issued a $21.00 price target on shares of Avadel Pharmaceuticals in a research report on Tuesday, March 4th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Avadel Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $19.88.
Get Our Latest Stock Analysis on Avadel Pharmaceuticals
Avadel Pharmaceuticals Company Profile
(
Get Free Report)
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
See Also
Before you consider Avadel Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avadel Pharmaceuticals wasn't on the list.
While Avadel Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
